Zoetis Inc. (NYSE:ZTS) Given Average Rating of “Hold” by Brokerages

Shares of Zoetis Inc. (NYSE:ZTS) have been assigned an average recommendation of “Hold” from the fifteen research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $133.0833.

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Stifel Nicolaus dropped their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th.

Zoetis Trading Down 2.3%

Shares of ZTS stock opened at $76.05 on Tuesday. The firm has a 50 day moving average price of $88.70 and a two-hundred day moving average price of $110.94. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $31.88 billion, a PE ratio of 12.61, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. Zoetis has a 12-month low of $72.38 and a 12-month high of $161.77.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts predict that Zoetis will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Insider Buying and Selling at Zoetis

In related news, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock worth $886,384 over the last three months. Corporate insiders own 0.22% of the company’s stock.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently bought and sold shares of ZTS. Nordea Investment Management AB grew its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the period. Seilern Investment Management Ltd grew its holdings in Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the period. Deutsche Bank AG grew its holdings in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares during the period. Assenagon Asset Management S.A. grew its holdings in Zoetis by 134.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares during the period. Finally, Pincus Capital Management LP acquired a new stake in Zoetis during the 4th quarter worth about $2,109,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, and others, announced or promoted class-action claims against Zoetis, increasing legal overhang and sentiment pressure on the stock.
• Neutral Sentiment: Zoetis also said it will host a webcast and conference call on August 6, 2026 to discuss second-quarter results, which may provide a more fundamental update for investors. Article Title

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.